Butterfly agrees to invest in MaryRuth Organics, GHO Capital agrees to acquire ClearView Healthcare Partners

Butterfly agrees to invest in MaryRuth Organics while GHO Capital is acquiring ClearView Healthcare Partners.

Happy Thursday!

Hope your week has been going well!

Here’s some emerging manager deal news: Butterfly, formed in 2015 by former execs of Vista Equity and KKR, agreed to invest in MaryRuth Organics, Inc., a wellness brand with a portfolio that includes vitamins, probiotics, herbal and adaptogen supplements and skin and beauty, among other things.

Founder and CEO MaryRuth Ghiyam, a certified health educator, nutritional consultant and culinary chef, started the business in Los Angeles. It’s expanded online and recently launched into retail channels, the firm said in a statement.

Ghiyam is said to have built up a loyal customer base and recently released a health lifestyle book called “Liquid Till Lunch”. Read more here on PE Hub.

Butterfly focuses on what it calls “seed to fork” investing that spans agriculture, aquaculture, food and beverage products, food distribution and foodservice.

In May, Butterfly announced a majority stake investment in Pete and Gerry’s Organics, a New Hampshire-based producer of organic eggs. British Columbia Investment Management Corp became a new minority investor in the company alongside Jesse Laflamme, Pete and Gerry’s CEO.

Butterfly is raising its sophomore fund this year targeting up to $750 million, for which it has held a first close, Buyouts exclusively reported in May. Butterfly closed its debut fund on $520 million in 2019, and also raised $320 million for a co-investment vehicle at the time.

Pharma services: GHO Capital agreed to acquire ClearView Healthcare Partners, concluding a Houlihan Lokey-run sale process for the life sciences consulting business. The deal is valued at about 17x ClearView’s marketed Ebitda of $43 million, Sarah writes on PE Hub today.

ClearView, founded in Boston in 2007, can be likened to a global strategy consulting firm like McKinsey & Co, but exclusively for the life sciences industry. Its consultants help pharmaceutical, biotech, medical devices and diagnostics companies globally.

GHO meanwhile is pushing deeper into North America. The London firm’s third pool recently closed on more than 2 billion euros, far exceeding its 1.25 billion euros target. Fund III is the largest European healthcare fund. Read more here.

That’s it for me! Have a great rest of your day. Hit me up with tips n’ gossip, feedback or book recommendations at cwitkowsky@buyoutsinsider.com or find me on LinkedIn.